Lexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtual Healthcare Conference

Written by Customer Service on September 3, 2020. Posted in Public Companies.

THE WOODLANDS, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conferences:Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020Jeffrey L. Wade, Lexicon’s executive vice president, corporate and administrative affairs and chief financial officer, will make a live webcast company presentation for the Wells Fargo conference on Thursday, September 10, 2020 at 2:00 p.m. ET. The webcast will be available in the “Events” section of the Lexicon website at www.lexpharma.com. An archived version of the webcast will be available on the website for two weeks.About Lexicon PharmaceuticalsLexicon is a fully integrated biopharmaceutical company with a mission...

Crinetics Pharmaceuticals to Participate in September Investor Conferences

Written by Customer Service on September 3, 2020. Posted in Public Companies.

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:Webcast Links:Links to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page in the Investors section on the Company’s website at www.crinetics.com. About Crinetics PharmaceuticalsCrinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor...

Altice USA, Inc. and Rogers Communications Provide Statement on Cogeco’s Response to Acquisition Offer

Written by Customer Service on September 3, 2020. Posted in Public Companies.

NEW YORK and TORONTO, Sept. 03, 2020 (GLOBE NEWSWIRE) — On the morning of September 2, 2020, Altice USA, Inc. (“Altice USA”) (NYSE: ATUS) announced that it had presented an offer to Cogeco Inc. (“CGO”) and Cogeco Communications Inc. (“CCA”, together with CGO, “Cogeco”) to acquire 100% of the issued and outstanding shares of Cogeco. Altice USA announced that it had also entered into an arrangement to sell all the Canadian assets of Cogeco to Rogers Communications Inc. (“Rogers”) (TSX:RCI.A and RCI.B, NYSE: RCI), Cogeco’s largest long-term shareholder with a significant presence in Quebec, if its transaction with Cogeco is completed. Upon completion of the overall transaction, Altice USA would own all the U.S. assets of Cogeco, namely Atlantic Broadband.On the evening of September 2, 2020, the Cogeco boards of directors announced...

Déclaration d’Altice USA, Inc. et de Rogers Communications sur la réponse de Cogeco à l’offre d’acquisition

Written by Customer Service on September 3, 2020. Posted in Public Companies.

NEW YORK et TORONTO, 03 sept. 2020 (GLOBE NEWSWIRE) — Dans la matinée du 2 septembre 2020, la société Altice USA, Inc. (« Altice USA ») (NYSE : ATUS) a annoncé qu’elle avait présenté une offre à Cogeco inc. (« CGO ») et à Cogeco Communications inc. (« CCA », conjointement avec CGO, « Cogeco ») en vue d’acquérir 100 % des actions émises et en circulation de Cogeco. Altice USA a annoncé qu’elle avait également conclu une entente pour vendre tous les actifs canadiens de Cogeco à Rogers Communications Inc. (« Rogers ») (TSX : RCI.A et RCI.B, NYSE : RCI), le plus important actionnaire de longue date de Cogeco, qui a une présence importante au Québec, si la transaction avec Cogeco se réalise. À l’issue de la transaction, Altice USA serait propriétaire de tous les actifs américains de Cogeco, exploités sous le nom Atlantic Broadband.Le...

Election of Lisa G. McMahon as Chairperson of Western New England Bancorp Board of Directors Highlights Board’s Commitment to Diversity

Written by Customer Service on September 3, 2020. Posted in Public Companies.

WESTFIELD, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) — Western New England Bancorp (NasdaqGS: WNEB) is pleased to announce that on March 24, 2020, Lisa G. McMahon of Westfield was elected Chairperson of Western New England Bancorp’s Board of Directors. Western New England Bancorp is the parent company of Westfield Bank, headquartered in Westfield, Massachusetts.Ms. McMahon’s historic appointment makes her the first female Board Chairperson in the organization’s 167-year history. Ms. McMahon succeeded former Board Chairperson Christos A. Tapases, a longtime and respected WNEB board member and successful business owner who passed away unexpectedly in March 2020.“While our hearts are still heavy following Chris’ sudden passing, we’re heartened to have a talented, hardworking, and community-focused executive like Lisa leading us into the...

International Display Advertising, Inc and ir Med Ltd Agree to Securities Exchange Agreement

Written by Customer Service on September 3, 2020. Posted in Public Companies.

New York, NY, Sept. 03, 2020 (GLOBE NEWSWIRE) — International Display Advertising, Inc. (OTCPINK: IDAD) announced today that it has entered into a Securities Exchange Agreement with IR Med Ltd., an Israeli company (“IR Med”) and the shareholders of IR Med pursuant to which IR Med would become a wholly owned subsidiary of IR Med, and the shareholders of IR Med would receive an aggregate of 31,043,945 shares of common stock of IDAD. The transaction is subject to closing conditions, including obtaining a tax ruling from the Israeli tax authorities and the closing of a private placement with net proceeds to IDAD of between approximately $1.8 million and $5 million. The holdings of the IR Med shareholders following the transaction will be between approximately 50% and 61% of the issued and outstanding share capital of IDAD, depending on...

ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 Million

Written by Customer Service on September 3, 2020. Posted in Public Companies.

GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the pricing of an underwritten equity offering and concurrent private placement transaction.H.C. Wainwright & Co. is acting as sole book-running manager for the underwritten offering and exclusive placement agent for the private placement.H.C. Wainwright & Co., as underwriter, has agreed to purchase on a firm commitment basis an aggregate of 6,448,240 units at an effective price of $2.869 per unit, less underwriting discounts and commissions. Each unit is comprised of one common share (or pre-funded warrant) and one 15-month purchase warrant to purchase one common...

Diversified Royalty Corp. Announces September 2020 Cash Dividend and Special Meeting Details

Written by Customer Service on September 3, 2020. Posted in Public Companies.

VANCOUVER, British Columbia, Sept. 03, 2020 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB) (the “Corporation” or “DIV”) is pleased to announce that its board of directors has approved a cash dividend of $0.01667 per common share for the period of September 1, 2020 to September 30, 2020, which is equal to $0.20 per common share on an annualized basis. The dividend will be paid on September 30, 2020 to shareholders of record as of the close of business on September 15, 2020.Special Meeting of ShareholdersThe Corporation will be holding a Special Meeting of shareholders at 9:00 am (Pacific time) on Wednesday, October 14, 2020 (the “Meeting”), where shareholders will be asked to consider and, if thought advisable, to pass a special resolution to approve the continuance of the Corporation from the Canada Business...

Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer

Written by Customer Service on September 3, 2020. Posted in Public Companies.

MONTREAL, Sept. 03, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced filing of the Supplement to a New Drug Submission (SNDS) of NERLYNX for HER2-Positive Metastatic Breast Cancer in Canada.NERLYNX was originally approved by Health Canada in July 2019 for the extended adjuvant treatment of women with early stage hormone receptor positive, HER2-overexpressed/amplified breast cancer within one year after completion of trastuzumab-based adjuvant therapy.1The SNDS is supported by the results of the Phase III NALA trial, a randomized controlled trial of neratinib plus capecitabine versus Tykerb® (lapatinib) plus capecitabine in HER2-positive metastatic breast cancer patients previously treated with ≥ 2 HER2-directed regimens.“We’re excited...

Thérapeutique Knight annonce le dépôt d’un supplément à la présentation de drogue nouvelle pour NERLYNX® (nératinib) pour le traitement du cancer du sein HER2-positif métastatique

Written by Customer Service on September 3, 2020. Posted in Public Companies.

MONTRÉAL, 03 sept. 2020 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (TSX : GUD) (« Knight ») société pharmaceutique spécialisée panaméricaine (ex-ÉU) et chef de file, a annoncé le dépôt d’un supplément à la présentation de drogue nouvelle (SPDN) pour NERLYNX pour le traitement du cancer du sein HER2-positif métastatique au Canada.NERLYNX a été initialement approuvé par Santé Canada en juillet 2019 aux fins du traitement adjuvant prolongé pour les femmes atteintes d’un cancer du sein au stade précoce avec récepteurs hormonaux positifs, surexprimés/amplifiés HER2, au cours de l’année suivant la fin du traitement adjuvant à base de trastuzumab.1Le SPDN est corroboré par les résultats de l’essai de phase III NALA, un essai contrôlé randomisé de nératinib plus capécitabine par rapport à Tykerb® (lapatinib) plus capécitabine sur des...

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Day: September 3, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice